URGN•benzinga•
UroGen Reported Updated 18-month Duration Of Response Data From The Phase 3 Envision Trial Of UGN-102 For Low-grade Intermediate Risk Non-muscle Invasive Bladder Cancer, With A DOR Rate Of 80.6% At 18-months Compared To 82.5% At 12-months
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga